NCT01278095

Oral Bioavailability of GLPG0555 in Different Solid Formulations

A Randomized, Open Label, 3-way Crossover Study to Compare the Oral Bioavailability of GLPG0555 After Single-dose Intake in Healthy Subjects as a Solid Dispersion Formulation, With and Without Food, Relative to a Nanosuspension Formulation

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of GLPG0555.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GLPG0555 solid dispersion	solid dispersion capsules, 50 mg, single dose
DRUG	GLPG0555 nanosuspension	Nanosuspension, 50 mg, single dose

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-02-01
• Completion: 2011-03-01
• First posted: 2011-01-17
• Last updated: 2011-03-24

Locations

1 site across 1 country: Belgium